The liver can regenerate, but certain risk factors — caused by our genetic or lifestyle — make liver cancer a prevalent and increasingly common form of cancer, at a time when cases of most other types of cancer are decreasing.
Changes have been made to tackle this issue, but the lack of available treatment options for liver cancer, and in particular hepatocellular carcinoma (HCC) —the most common form of liver cancer — pose a great challenge.
Fortunately, technology and advanced diagnostic tools have transformed the way liver cancer is diagnosed. The latest developments in surveillance methods, such as using ultrasound imaging in combination with measuring AFP levels twice a year, in the HCC high-risk population have become more efficient, especially for hepatitis B and C carriers, or patients who have liver cirrhosis.
Our ambition is to continue making advances in the field of liver cancer, so that we can improve the lives of those affected by it. We believe people with HCC deserve more options, and our hope for the future is to be a helping hand for those who need it.
Despite great advances in screening, vaccinations and treatment development, further research and understanding is needed to curb the spread of liver cancer. Indeed, unlike other types of cancer, which may be caused by a small number of clearly defined genetic mutations, liver cancer has complex mechanisms that often vary from patient to patient and depend on the different disease stages. For instance, targeted therapy and immunotherapy may work for some patients but not others.
Our focus lies in understanding why so that we can develop treatment solutions tailored to patients' individual tumours.
© 2023, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.
M-NZ-00000625-v6.0/MR9618/NOV23. This site was last updated NOV2023